To date, numerous PGK1 blockers, such as CBR-470-1, NG52, and GQQ-792, have been developed as potential anti-cancer drugs with inhibitory mechanisms on tumor growth, metastasis, the epithelial–mesenchymal transition process, as well as chemotherapy resistance [51,52,53]. This evidence concerns the gene PGK1 and neoplasm.